Medicure's Vice President of Business Development, Reuben Saba Honored Among the 50 Most Influential Leaders in US Pharmacy Space

Medicure's Vice President of Business Development, Reuben Saba, was honored as one of the most influential leaders in the US pharmacy space.

The 50 Most Influential Leaders in Pharmacy program was launched in 2021 by the Pharmacy Podcast Network as a way to draw attention to industry professionals whose thoughts, actions, accomplishments and leadership have helped solve clinical, customer service and financial problems.

You can learn more about the award here:

Pharmacy Podcast Network

When asked what the award meant to him, Reuben said:

To me, as the Business Development Lead at Marley Drug, a pharmacy uniquely licensed in all 50 US states and provides access to cost effective prescription medication, pharmacy leadership signifies a commitment to both innovation and service.

It means staying on top of industry advancements and innovation and leveraging them to enhance our operational efficiency and customer service at Marley Drug.

It involves leading by example, fostering a culture that prioritizes patient care, and empowering our team to go the extra mile in delivering quality health solutions to all our customers across the US.

Ultimately, it's about steering the Marley Drug Brand towards growth and success, while staying true to our mission of improving health outcomes for all Americans.

Why We Acquired Marley Drug

Medicure Inc.'s recent acquisition of Marley Drug demonstrates its commitment to addressing the rising cost of prescription medications in the United States.

Meet our VP of Medical and Business Affairs

We sat down with our Vice President of Medical and Business Affairs to learn a bit more about them.
Reuben Saba, Ph.D. is the Vice President of Medical and Business Affairs at Medicure.

Medicure Acquires Marley Drug Pharmacy To Distribute Low-Cost Medications

In 2017, Medicure expanded its portfolio into the primary care market and began marketing Zypitamag (pitavastatin) tablets, a next-generation statin. This was a pharmaceutical alternative to a branded competitor with an established market share